- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Phase II trial results indicated that treatment with the firm's antisense oligonucleotide led to stable or improved best-corrected visual acuity.

Researchers reviewed the need for supplemental aflibercept injections and overall treatment burden in eyes being treated for ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Researchers evaluated real-world data to extend treatment intervals, maintain BCVA, and achieve macular fluid resolution ...

Vanotech is the sponsor representative and is responsible for the clinical development programme for the therapy in the US.

Erie International Airport is teaming up with Erie Retina Research to increase vision awareness for travelers while they wait ...

D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and ...

A new study shows that tiny gold particles could circumvent damaged photoreceptors in patients with macular degeneration and ...

Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating ...

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical ...